Florian Muellershausen

F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom.

Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.

Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Rappta Therapeutics Oy operates as a biopharmaceutical company. It develops anti-cancer drugs activating protein phosphatase 2A. The company was founded by Goutham Narla and Mikko Lauri Sampsa Mannerkoski on March 20, 2019 and is headquartered in Helsinki, Finland.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium.

Fore Biotherapeutics, Inc. develops tumor specific driver mutations. It offers fully automated live-cell screening from NGS data. The company was founded by Haim Gil-Ad and Yoram Altschuler in 2011 and is headquartered in Philadelphia, PA.

Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom.

Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.

MISSION Therapeutics Ltd. develops small molecule drugs targeting enzymes involved in cancer and other diseases. It focuses on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company was founded by Stephen Jackson Philip, Xavier Jacq, Niall M. B. Martin and Keith Menear in 2011 and is headquartered in Cambridge, the United Kingdom.

Founded in 1996, Novartis Venture Funds (USA) is a venture capital firm located in Cambridge, Massachusetts. The firm is a subsidiary of Switzerland-based Novartis Venture Funds and their ultimate parent is Novartis AG, a Switzerland-based company that engages in the research, development, manufacturing and marketing of healthcare products. Novartis Venture Funds manages the Bermuda domiciled biotechnology venture fund, Novartis BioVentures Ltd

Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland.

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

N T B Pharma Ltd. provides scientific and technical research development services. The private company is based in Herzliya, Israel.

cCAM Biotherapeutics Ltd. is a preclinical-stage company engaging in the development of immunotherapies to treat cancer. The company was founded by Silvia Noiman and Gal Markel in 2010 and is headquartered in Hod Ha'Sharon, Israel.

Nutrinia Ltd. develops bioactive feed supplements for infant formulas and animal feed. The firm is involved in broad intellectual property protection, industrial processes envelopment, conducting additional clinical trials and obtaining regulatory approval for the supplementation of pre-term and infant formulas with Insulin. The company was founded by Naim Shehadeh in 2003 and is headquartered in Ramat-Gan, Israel.

CollPlant Ltd. specializes in the development and commercialization of medical products. It develops and commercialize tissue repair products for orthobiologics and advanced wound care markets. The company was founded by Tsafrir Feigin Yehuda and Oded Shoseyov in 2004 and is headquartered in Ness Ziona, Israel.

Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.

OCON Medical Ltd. engages in the research and development of intrauterine device. Its products include Intrauterine Ball IUB and IUB SCu300. The company was founded by Ilan Baram on 2008 and is headquartered in Modiin, Israel.

Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel.

Aliment Capital LLC (Aliment Capital) is a venture capital subsidiary of Pontifax Management Co. Ltd. founded in 2014 by Philip Robert Erlanger and Ben Belldegrun. The firm is headquartered in California, United States.

Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland.

Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom.

Indapta Therapeutics, Inc. operates as a biotechnology company. It focuses on developing and commercializing a proprietary, first-in-class, off-the-shelf allogeneic cell therapy to treat multiple types of difficult-to-treat hematologic cancers and solid tumors. The company was founded by Guy DiPierro, Ronald A. Martell, Sungjin Kim and John Sunwoo in 2017 and is headquartered in Houston, TX.

Graviton Bioscience Corp. develops novel therapeutics for the treatment of autoimmune, cancer, genetic, fibrotic and other serious diseases. The company is based in New York, NY. The company was founded by Samuel D. Waksal. Samuel D. Waksal has been the CEO since incorporation.

LB Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded by Vince Grattan and Zachary Prensky in 2015 and is headquartered in New York, NY.

Part of Pontifax Management Co. Ltd., Pontifax (Israel) IV LP is an investment services provider. The company is based in Hertsliya, Israel and was founded in 2015.